News
Theresa Tse Attends WCE Summit: AI-Driven Global Pharmaceutical Innovation and the Power of Women in an Open Ecosystem
Release Date: 2026-11-03
On November 2, the Women Chief Executives Summit 2026 (WCE Summit 2026) was held in Hong Kong. Themed "Female Voices of Impact and Innovation," this year's summit brought together over 400 global industry leaders to discuss how companies can respond to change, seize opportunities, and achieve sustainable development. Theresa Tse, Chairman of the Board of Sino Biopharmaceutical Limited (SBP Group, 01177.HK), was invited to attend and elaborated on her thoughts on "AI for Science" and global pharmaceutical cooperation.
AI Accelerates New Drug R&D, Creating New Opportunities for Global Collaboration in China's Innovative Pharmaceutical Industry
![]()
In recent years, China's pharmaceutical industry has been in a critical period of its globalization process. In the first three quarters of 2026 alone, the total value of out-licensing deals for China's innovative drugs has exceeded 130 billion US dollars. Global cooperation and out-licensing are becoming important ways to drive the realization of innovative value in the biopharmaceutical industry. Theresa Tse stated, "The development of "AI for Science" will accelerate the discovery and development of innovative drugs and propel global pharmaceutical cooperation into a new stage of advancement." With its efficient clinical trials and the rapid development of AI-powered drug development, China will become more deeply integrated into the global pharmaceutical innovation chain and play an "extremely critical role".
As a key participant in the wave of globalization, AI has already become a major driving force for SBP Group in enhancing its operational and R&D efficiency. SBP Group's financial data for the first half of 2026 shows that, excluding factors such as dividend income, the adjusted net profit attributable to the parent company from core business increased by 92.3% year-on-year, with AI playing a significant role in improving efficiency across the entire value chain. Currently, SBP Group has over 100 innovative pipelines under development, with AI-powered drug development empowering 25 early research stage and 37 clinical stage pipelines.
Women's Health, Women's Empowerment and Global Innovation in an Open Ecosystem
![]()
As an innovative pharmaceutical company with a female Chairman of the Board, SBP Group has long focused on women's health needs and actively promoted the development of female talent. Currently, the company has invested a total of approximately 3 billion RMB in R&D in the field of women's health, focusing on common female neoplasms such as breast cancer and ovarian cancer, as well as disease areas with significant unmet clinical needs. Its marketed products have benefited a cumulative total of about 600,000 women. In terms of career growth and leadership development, the proportion of women in leadership positions one level below the Chairman of the Board has increased to 59%.
Theresa Tse stated, "We are in an era that fully empowers women, where women's education, career development, and personal aspirations are fully respected." As a female leader of the younger generation, she believes that everyone should have equal opportunities for development. "The standard for measuring whether a person can take on leadership responsibilities should be their ability, and the company encourages every capable talent to proactively take on responsibilities and exercise leadership."
![]()
Talent is the most core asset of a company, and SBP Group has always gathered global talent with an open and flexible philosophy. Whether through internal talent development or external cooperation, Theresa Tse said that SBP Group continuously strengthens its extensive connections with global scientists, university professors, startups, biotech companies, and multinational pharmaceutical companies, bringing together top talent, professional technologies, and diverse perspectives from the entire industry ecosystem. "It is by relying on this vast global talent network that we can continuously stay at the forefront of innovation and keep up with cutting-edge market trends."
Declaration:
The copyright of this article is owned by the original author or the Company. It may not be used by reprinting, copying, filming, adapting, compiling, or other means without authorization. The portrait rights of the individuals appearing in this article belong to the individuals themselves. Unauthorized use is prohibited.
